

■ **The peptide-containing, synthetic surfactant sinapultide^{*} may confer survival benefit in premature neonates**, according to results from a pooled analysis of the SELECT and STAR trials presented at the Pediatric Societies' Annual Meeting in Washington D.C., US. Premature neonates received sinapultide or one of two animal-derived surfactants. Treatment with sinapultide conferred survival benefit at 1 year of life.

* Discovery Laboratories, Esteve; preregistration in EU and US, phase III in South America for neonatal respiratory distress syndrome

Discovery Labs. New Data Shows Discovery's Surfaxin(r) Survival Benefit Continues Through One Year of Life. Media Release : 18 May 2005.

Available from: URL: <http://www.DiscoveryLabs.com>

809049545